Silexion regains Nasdaq compliance with $9.4M equity after capital raise

Silexion Therapeutics Corp

Issued 450,000 shares to sponsor upon converting $1.8M of convertible note at $4.00/share; remaining $1.6M outstanding.
Shareholders' equity rose to ~$9.4M from -$0.7M at July 31, 2025, after four transactions.
Company affirms compliance with Nasdaq Capital Market equity requirement of $2.5M and expects long-term compliance.
Gross proceeds from September 2025 public offering: ~$6.0M from sale of shares/pre-funded warrants and warrants.
Warrant exercise inducement in August 2025 generated ~$1.8M gross proceeds.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Silexion Therapeutics Corp issued 450,000 ordinary shares of common stock to Moringa Sponsor, LP for $1.8 million of the outstanding amount under the Amended and Restated Promissory Note.

Security: common stock
Shares: 450,000 ordinary shares
Purchaser: Moringa Sponsor, LP
Consideration: $1.8 million of the outstanding amount under the Amended and Restated Promissory Note

Exact text from the filing

On September 15, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company (“ Silexion ” or the “ Company ”) issued 450,000 ordinary shares, par value $0.0135 per share, of Silexion (“ ordinary shares ”), to Moringa Sponsor, LP (the “ Sponsor ”) upon conversion by Silexion of an aggregate of $1.8 million of the outstanding amount under the Amended and Restated Promissory Note, dated August 15, 2024, in an original principal amount of $3.4 million (the “ Sponsor Convertible Note ”), issued by Silexion to the Sponsor.

View on SEC.gov

Browse all equity issuances →

Silexion Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001178913-25-003329

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.